Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human epidermal growth factor receptor 2-targeted dual-payload antibody-drug conjugate ...

BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that ...

Experts at ADC Bio warn of impending problems in the ADC pipeline with millions wasted in development costs 14 November 2017, Wales: ADC Biotechnology (ADC Bio)‘s leading experts warn that best in ...

MUNICH--(BUSINESS WIRE)--Tubulis today announced the appointment of Björn Hock, PhD, as Chief Development Officer (CDO) to further strengthen its leadership team with a seasoned drug development ...

The CDMO is striving to become a market leader in the development and manufacturing of antibody-drug conjugates. Piramal Enterprises' Pharma Solutions division announced that it is looking to ...

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX ...

BOSTON, March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a ...

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and ...